Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials
Salvatore Cassese, Sebastian Kufner, Erion Xhepa, Robert A Byrne, Johanna Kreutzer, Tareq Ibrahim, Klaus Tiroch, Marco Valgimigli, Ralph Tölg, Massimiliano Fusaro, Heribert Schunkert, Karl-Ludwig Laugwitz, Julinda Mehilli, Adnan Kastrati, Salvatore Cassese, Sebastian Kufner, Erion Xhepa, Robert A Byrne, Johanna Kreutzer, Tareq Ibrahim, Klaus Tiroch, Marco Valgimigli, Ralph Tölg, Massimiliano Fusaro, Heribert Schunkert, Karl-Ludwig Laugwitz, Julinda Mehilli, Adnan Kastrati
Abstract
Background: In percutaneous coronary intervention (PCI) patients new-generation drug-eluting stent (DES) has reduced adverse events in comparison to early-generation DES. The aim of the current study was to investigate the long-term clinical efficacy and safety of new-generation DES versus early-generation DES for PCI of unprotected left main coronary artery (uLMCA) disease.
Methods: The patient-level data from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 randomized trials were pooled. The clinical outcomes of PCI patients assigned to new-generation DES (everolimus- or zotarolimus-eluting stent) versus early-generation DES (paclitaxel- or sirolimus-eluting stent) were studied. The primary endpoint was the composite of death, myocardial infarction (MI), target lesion revascularization and stroke (MACCE, major adverse cardiac and cerebrovascular event).
Results: In total, 1257 patients were available. At 3 years, the risk of MACCE was comparable between patients assigned to new-generation DES or early-generation DES (28.2 versus 27.5 %, hazard ratio-HR 1.03, 95 % confidence intervals-CI 0.83-1.26; P = 0.86). Definite/probable stent thrombosis was low and comparable between new-generation DES and early-generation DES (0.8 versus 1.6 %, HR 0.52, 95 % CI 0.18-1.57; P = 0.25); in patients treated with new-generation DES no cases occurred beyond 30 days. Diabetes increased the risk of MACCE in patients treated with new-generation DES but not with early-generation DES (P interaction = 0.004).
Conclusions: At 3-year follow-up, a PCI with new-generation DES for uLMCA disease shows comparable efficacy to early-generation DES. Rates of stent thrombosis were low in both groups. Diabetes significantly impacts the risk of MACCE at 3 years in patients treated with new-generation DES for uLMCA disease. ClinicalTrials.gov Identifiers: NCT00133237; NCT00598637.
Keywords: Drug-eluting stent; Everolimus; Left main coronary artery; Paclitaxel; Percutaneous coronary intervention; Sirolimus; Zotarolimus.
References
- J Am Coll Cardiol. 2014 Feb 4;63(4):299-307
- Circulation. 2012 Jun 12;125(23):2873-91
- Clin Res Cardiol. 2013 Sep;102(9):679-86
- J Am Coll Cardiol. 2011 Feb 1;57(5):538-45
- J Am Coll Cardiol. 2009 May 12;53(19):1760-8
- J Am Coll Cardiol. 2015 May 26;65(20):2198-206
- Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1500-10
- JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74
- Circulation. 2014 Jun 10;129(23):2388-94
- J Am Coll Cardiol. 2013 Dec 3;62(22):2075-82
- Eur Heart J. 2012 May;33(10):1214-22
- J Am Coll Cardiol. 2008 Jul 29;52(5):333-42
- Heart. 2014 Jan;100(2):153-9
- J Am Coll Cardiol. 2006 Jul 4;48(1):193-202
- Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1473-80
- Circ Cardiovasc Interv. 2014 Aug;7(4):518-25
- J Am Coll Cardiol. 2014 Nov 4;64(18):1929-49
- Clin Res Cardiol. 2013 May;102(5):371-81
- Circ Cardiovasc Interv. 2015 Mar;8(3):e001846
- JACC Cardiovasc Interv. 2013 Dec;6(12):1219-30
- Eur Heart J. 2014 May;35(17):1147-58
- J Am Coll Cardiol. 2013 Dec 24;62(25):2360-9
- EuroIntervention. 2015 ;11 Suppl V:V115-9
- Lancet Diabetes Endocrinol. 2013 Dec;1(4):317-28
- JAMA. 2007 May 9;297(18):1992-2000
- Am J Cardiol. 2013 Mar 1;111(5):676-83
- Circulation. 2010 Mar 16;121(10):1235-43
- J Am Coll Cardiol. 2014 Sep 23;64(12):1189-97
- J Am Coll Cardiol. 2007 Aug 7;50(6):498-500
- Circulation. 2011 Aug 23;124(8):893-900
- Eur Heart J. 2014 Oct 1;35(37):2541-619
- BMJ. 2013 Nov 08;347:f6625
- Circulation. 2013 Jun 4;127(22):2177-85
- Eur Heart J. 2011 Sep;32(17):2125-34
Source: PubMed